Eterna Therapeutics

ERNA

Market cap $9.9M

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its upcoming company presentation at the Cell & Gene Meeting on the Mesa , taking place on October 7 in Phoenix, Arizona, and virtually online.

CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjeev Luther, will participate in a featured panel discussion at the upcoming 5th Annual iPSC Drug Development Summit on October 1 in Boston.

Presentation to highlight preclinical data from the company's lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trials Presentation to highlight preclinical data from the company's lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trials

CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provided an update on its operational excellence and performance for the first half of 2025.

CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will be featured as a presenting company at the H.C. Wainwright 27th Annual Global Investment Conference , being held September 8–10, 2025.

CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) --   Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market.

Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa's Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa's Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs

Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives

CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the “Common Stock”), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.”

New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes